SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2022 / Cilt: 60 - Sayı: 3

Aberrant Activation-Induced Cytidine Deaminase Gene Expression Links BCR/ABL1-Negative Classical Myeloproliferative Neoplasms

Hasan DERMENCİ
Veysel Sabri HANÇER
Aysegul Basak AKADAM TEKER
Akif Selim YAVUZ
Aynur DAĞLAR ADAY
Meliha NALCACI
Metin Yusuf GELMEZ
Pages
228–233
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: AID expression levels were significantly higher in the patient group compared to the control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Activation-induced cytidine deaminase (AID) has been associated with tumor initiation and development because of its ability to generate DNA damage and somatic mutations that cause genomic instability.
📊
Key Findings & Data:This study aimed to investigate the relationship between AID expression levels and the risk of developing BCR/ABL1-negative myeloproliferative neoplasms (MPNs) by comparing the AID expression levels of the patients and controls.
💡
Conclusion & Impact:Results: AID expression levels were significantly higher in the patient group compared to the control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Activation-induced cytidine deaminase (AID) has been associated with tumor initiation and development because of its ability to generate DNA damage and somatic mutations that cause genomic instability. This study aimed to investigate the relationship between AID expression levels and the risk of developing BCR/ABL1-negative myeloproliferative neoplasms (MPNs) by comparing the AID expression levels of the patients and controls. Methods: This case-control study was conducted on 117 cases (64 essential thrombocythemia, 23 primary myelofibrosis, and 30 polycythemia vera) with MPNs and 69 healthy controls. The JAK2 V617F somatic mutation analysis was performed using a real-time polymerase chain reaction (RT-PCR). The relative expression levels of AID in the patient and the control groups were analyzed using quantitative RT-PCR and the 2-ΔΔCT method. Results: AID expression levels were significantly higher in the patient group compared to the control group (p

🔖

Cite This Article

DERMENCİ, H., HANÇER, V. S., TEKER, A. B. A., YAVUZ, A. S., ADAY, A. D., NALCACI, M., GELMEZ, M. Y. (2022). Aberrant Activation-Induced Cytidine Deaminase Gene Expression Links BCR/ABL1-Negative Classical Myeloproliferative Neoplasms. Haseki Tıp Bülteni, Cilt: 60 - Sayı: 3, 228–233. https://ajindex.com/articles/534937

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol 2016;91:50-8
  2. Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica 2017;102:7-17
  3. Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood 2017;130:2475-83
  4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61
  5. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207-9
  6. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-52
  7. Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993;260:1816-9
  8. Muñoz DP, Lee EL, Takayama S, et al. Activation-induced cytidine deaminase (AID) is necessary for the epithelialmesenchymal transition in mammary epithelial cells. Proc Natl Acad Sci U S A 2013;110:E2977-86
  9. Sablitzky F, Wildner G, Rajewsky K. Somatic mutation and clonal expansion of B cells in an antigen-driven immune response. EMBO J 1985;4:345-50
  10. Hu D, Zheng H, Liu H, et al. Immunoglobulin expression and its biological significance in cancer cells. Cell Mol Immunol 2008;5:319-24
  11. Chen Z, Qiu X, Gu J. Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. Am J Pathol 2009;174:1139-48
  12. Rios LAS, Cloete B, Mowla S. Activation-induced cytidine deaminase: in sickness and in health. J Cancer Res Clin Oncol 2020;146:2721-30
  13. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22
  14. Rebhandl S, Huemer M, Greil R, Geisberger R. AID/APOBEC deaminases and cancer. Oncoscience 2015;2:320-33
  15. Pavri R, Nussenzweig MC. AID targeting in antibody diversity. Adv Immunol 2011;110:1-26
  16. Hancer VS, Kose M, Diz-Kucukkaya R, Yavuz AS, Aktan M. Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:79- 84
  17. Edry E, Azulay-Debby H, Melamed D. TOLL-like receptor ligands stimulate aberrant class